Treatment of antisynthetase-associated interstitial lung disease with tacrolimus

Arthritis and Rheumatism

Volumn 52, Issue 8, 2005, Pages 2439-2446

  Wilkes, Margaret R ^a   Sereika, Susan M ^a   Fertig, Noreen ^a   Lucas, Mary R ^a   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; AZATHIOPRINE; CREATINE KINASE; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MAGNESIUM; METHOTREXATE; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FORCED EXPIRATORY VOLUME; GYNECOMASTIA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG FUNCTION TEST; MALE; MUSCLE STRENGTH; MYOPATHY; MYOSITIS; NEPHROTOXICITY; POLYMYOSITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREMOR;

ADULT; AGED; ALANINE-TRNA LIGASE; AMINO ACYL-TRNA SYNTHETASES; AUTOANTIBODIES; COHORT STUDIES; FEMALE; HISTIDINE-TRNA LIGASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOSITIS; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 23644453951     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21240     Document Type: Article

References (34)

1. Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: associations with interstitial pulmonary disease. J Rheumatol 1984;11:663-5.
2. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992;35:821-30.
3. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990;88:241-51.
4. Marguerie C, Bunn CC, Beynon HC, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes [review]. Q J Med 1990; 77:1019-38.
5. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
6. Bernstein RM, Morgan SH, Chapman J, Bunn CC, Mathews MB, Turner-Warwick M, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984;289:151-2.
7. Hirakata M, Suwa A, Nagai S, Kron M, Trieu EP, Mimori T, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999;162:2315-20.
8. Oddis CV, Medsger TA Jr, Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum 1990;33:1640-5.
9. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32:273-84.
10. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1762-3.
11. Kendall FP. Key to muscle grading: muscles: testing and function. Baltimore: Williams & Wilkins; 1993. p. 188-92.
12. Bohan A, Peter J. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
13. Yamanishi Y, Maeda H, Konishi F, Hiyama K, Yamana S, Ishioka S, et al. Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. Scand J Rheumatol 1999;28:58-61.
14. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995;35:1519-23.
15. Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 1999;18:462-7.
16. Grau JM, Miro O, Pedrol E, Casademont J, Masanes F, Herrero C, et al. Interstitial lung disease related to dermatomyositis: comparative study with patients without lung involvement. J Rheumatol 1996;23:1921-6.
17. Yoshida T, Koga H, Saitoh F, Sakamoto M, Harada M, Yoshida H, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999;38:733-8.
18. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
19. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporin as a treatment for interstitial lung disease of unknown etiology. Thorax 1991;46:592-5.
20. Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporin treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis. Scand J Rheumatol 1997;26:24-9.
21. Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in polymyositis/ dermatomyositis: prediction and treatment with cyclosporin A. J Rheumatol 1999;26:1527-33.
22. Kobayashi K, Yamada M, Takahashi Y, Kawamura N, Okano M, Sakiyama Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003;42:371-4.
23. Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002;129:541-8.
24. Plosker G, Foster R. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000;59:323-89.
25. Van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002;25:707-12.
26. Christians U, Jacobsen W, Benet L, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus [review]. Clin Pharmacokinet 2002;41:813-51.
27. Tanaka H, Kuroda A, Marusawa H, Hashimoto M, Hatanaka H, Kino T, et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19 Suppl 6:11-6.
28. Kino T, Katanaka K, Hashimoto H, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation, isolation, and physico-chemical and biologic characteristics. J Antibiot (Tokyo) 1987;40: 1249-55.
29. Thomson A, Carroll P, McCauley J, Woo J, Abu-Elmagd K, Starzl TE, et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease: rationale and preliminary clinical experience at the University of Pittsburgh [review]. Springer Semin Immunopathol 1993;14:323-44.
30. Kainz A, Harabacz I, Cowlrick I, Gadgil S, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000;70:1718-21.
31. Kruszka SJ, Gherman RB. Successful pregnancy outcome in a lung transplant recipient with tacrolimus immunosuppression: a case report. J Reprod Med 2002;47:60-2.
32. Friedman A, Targoff I, Arnett F. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
33. Xaubet A, Agusti C, Luburich P, Roca J, Monton C, Ayuso MC, et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:431-6.
34. Flaherty K, Martinez F. The role of pulmonary function testing in pulmonary fibrosis. Curr Opin Pulm Med 2000;6:404-10.